Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy.
Dyslipidemia has been identified as an important pathogenic risk factor for diabetic neuropathy, but current animal models do not adequately reproduce the lipid profile observed in human diabetics (increased triglycerides with an elevated LDL-cholesterol and reduced HDL-cholesterol). High fat feeding of mice produces hyperlipidemia, but mice are resistant to increases in the LDL to HDL ratio, reducing the potential for peripheral lipid deposits to impact neuropathy, as is postulated to occur in human subjects. Genetic manipulations provide an alternative approach to reproducing a neuropathic plasma lipid profile. Based on findings from the atherosclerosis literature, we began with knockout of ApoE. Since knockout of ApoE alone only partially mimics the human diabetic lipid profile, we examined the impact of its combination with a well-characterized model of type 2 diabetes exhibiting neuropathy, the db/db mouse. We added further gene manipulations to increase hyperlipidemia by using mice with both ApoE and ApoB48 knockout on the ob/+ (leptin mutation) mice. In all of these models, we found that either the db/db or ob/ob genotypes had increased body weight, hyperlipidemia, hyperglycemia, and evidence of neuropathy compared with the control groups (db/+ or ob/+, respectively). We found that ApoE knockout combined with leptin receptor knockout produced a lipid profile most closely modeling human dyslipidemia that promotes neuropathy. ApoE knockout combined with additional ApoB48 and leptin knockout produced similar changes of smaller magnitude, but, notably, an increase in HDL-cholesterol. Our data suggest that the overall effects of ApoE knockout, either directly upon nerve structure and function or indirectly on lipid metabolism, are insufficient to significantly alter the course of diabetic neuropathy. Although these models ultimately do not deliver optimal lipid profiles for translational diabetic neuropathy research, they do present glycemic and lipid profile properties of value for future therapeutic investigations.
Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
Lucy M
LM
Hinder
Andrea M
AM
Vincent
John M
JM
Hayes
Lisa L
LL
McLean
Eva L
EL
Feldman
D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics* / Q000502:physiology*; D001522:Behavior, Animal / Q000502:physiology; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D002784:Cholesterol / Q000097:blood; D003627:Data Interpretation, Statistical; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000150:complications / Q000235:genetics* / Q000473:pathology*; D055724:Electrophysiological Phenomena; D020738:Leptin / Q000235:genetics; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000235:genetics* / Q000473:pathology*; D014280:Triglycerides / Q000097:blood
D001057:Apolipoproteins E; D001786:Blood Glucose; D020738:Leptin; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol